Altering PPAR γ ligand selectivity impairs adipogenesis by thiazolidinediones but not hormonal inducers

Obesity

Volumn 17, Issue 5, 2009, Pages 965-972

  Samarasinghe, Shanika P ^a   Sutanto, Maria M ^a   Danos, Arpad M ^a   Johnson, Daniel N ^a   Brady, Matthew J ^a   Cohen, Ronald N ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRIDAE; MURINAE;

2,4 THIAZOLIDINEDIONE DERIVATIVE; DEXAMETHASONE; DNA BINDING PROTEIN; GLUTATHIONE TRANSFERASE; INSULIN; NUCLEAR RECEPTOR CO-REPRESSOR 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRIMER DNA; REPRESSOR PROTEIN; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR;

ADIPOCYTE; AMINO ACID SUBSTITUTION; ANIMAL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR CLONING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; PLASMID; SITE DIRECTED MUTAGENESIS;

3T3 CELLS; ADIPOCYTES; AMINO ACID SUBSTITUTION; ANIMALS; CELL DIFFERENTIATION; CLONING, MOLECULAR; DEXAMETHASONE; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENE SILENCING; GLUTATHIONE TRANSFERASE; INSULIN; MICE; MUTAGENESIS, SITE-DIRECTED; PLASMIDS; PPAR GAMMA; RECEPTORS, THYROID HORMONE; REPRESSOR PROTEINS; THIAZOLIDINEDIONES; TRANSFECTION;

EID: 67349224681     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.629     Document Type: Article

References (36)

1. Kodera Y, Takeyama K, Murayama A et al. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J Biol Chem 2000;275:33201 -33204.
2. Mettu NB, Stanley TB, Dwyer MA et al. The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Mol Endocrinol 2007;21:2361-2377.
3. Nolte RT, Wisely GB, Westin S et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998;395:137-143.
4. Rosen ED, Spiegelman BM. PPAR gamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001 ;276:37731-37734.
5. Nagai S, Shimizu C, Umetsu M et al. Identification of a functional peroxisome proliferator-activated receptor responsive element within the murine perilipin gene. Endocrinology 2004;145:2346-2356.
6. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Corepressors selectively control the transcriptional activity of PPAR gamma in adipocytes. Genes Dev 2005;19:453-461.
7. Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003;52:1655-1663.
8. Yu C, Markan K, Temple KA et al. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis. J Biol Chem 2005;280:13600-13605.
9. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454-457.
10. Horlein AJ, Naar AM, Heinzel T et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995:377:397-404.
11. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-2556.
12. Gelman L, Zhou G, Fajas L et al. p300 interacts with the N- and C-terminal part of PPAR gamma2 in a ligand-independent and -dependent manner, respectively. J Biol Chem 1999;274:7681 -7688.
13. Zhu Y, Qi C, Jain S, Rao MS, Reddy JK. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem 1997;272:25500-25506.
14. Puigserver R Wu Z, Park CW et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998;92:829-839.
15. Tzameli I, Fang H, Ollero M et al. Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J Biol Chem 2004;279:36093-36102.
16. Lehmann JM, Moore LB, Smith-Oliver TA et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-12956.
17. Xu HE, Lambert MH, Montana VG et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 2001 ;98:13919-13924.
18. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-688.
19. Keller H, Devchand PR, Perroud M, Wahli W. PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem 1997;378:651-655.
20. Cohen RN, Putney A, Wondisford FE, Hollenberg AN. The nuclear corepressors recognize distinct nuclear receptor complexes. Mol Endocrinol 2000;14:900-914.
21. Kliewer SA, Forman BM, Blumberg B et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994;91:7355-7359.
22. Greenberg CC, Meredith KN, Yan L, Brady MJ. Protein targeting to glycogen overexpression results in the specific enhancement of glycogen storage in 3T3-L1 adipocytes. J Biol Chem 2003;278: 30835-30842.
23. Hamm JK, Park BH, Farmer SR. A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes. J Bol Chem 2001 ;276: 18464-18471.
24. Rosen ED. The transcriptional basis of adipocyte development. Prostaglandins Leukot Essent Fatty Acids 2005;73:31-34.
25. Kliewer SA, Sundseth SS, Jones SA et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997;94:4318-4323.
26. Mclntyre TM, Pontsler AV, Silva AR et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR gamma agonist. Proc Natl Acad Sci USA 2003;100:131-136.
27. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma. Cell 1998;93:229-240.
28. Lazar MA. PPAR gamma, 10 years later. Biochimie 2005;87:9-13.
29. Agostini M, Gurnell M, Savage DB et al. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology 2004;145:1527-1538.
30. Gurnell M, Wentworth JM, Agostini M et al. A dominant-negative peroxisome proliferator-activated receptor gamma (PPAR gamma) mutant is a constitutive repressor and inhibits PPAR gamma-mediated adipogenesis. J Biol Chem 2000;275:5754-5759.
31. Park Y, Freedman BD, Lee EJ, Park S, Jameson JL. A dominant negative PPAR gamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia 2003;46:365-377.
32. Wong WT, Nick HS, Frost SC. Regulation of annexin I in adipogenesis: cAMP-independent action of methylisobutylxanthine. Am J Physiol 1992;262:C91-C97.
33. Walkey CJ, Spiegelman BM. A functional PPAR gamma ligand binding domain is not required for adipogenesis. J Biol Chem 2008;283:24290-24294.
34. Sears DD, Hsiao A, Ofrecio JM et al. Selective modulation of promoter recruitment and transcriptional activity of PPAR gamma. Biochem Biophys Res Commun 2007;364:515-521.
35. Zhang F, Lavan BE, Grégoire FM. Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects. PPAR Res 2007;2007:32696.
36. Berger JP, Petro AE, Macnaul KL et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003; 17:662-676.